Platform Evolution: A Technological Leap of Biopsy Needles from Sampling Tools to Integrated Diagnostic Systems

Keywords: Intelligent Biopsy Needle Platform + Real-time In Vivo Analysis and Targeted Therapy Guidance

The ultimate evolutionary direction of modern biopsy needles is to transcend the single function of tissue sampling, and evolve into miniature diagnosis and treatment platforms integrating in vivo diagnosis, precise sampling, real-time feedback, and targeted therapy. Essentially, this transformation upgrades biopsy needles from passive tissue-harvesting instruments to active nodes for clinical decision-making. Within the tiny space of the needle tip, complex functions that previously required multiple large-scale medical devices can now be accomplished.

Integration of multimodal sensors initiates the era of in vivo pathology. Traditional biopsy relies on an ex vivo workflow of sampling, fixation, slicing, staining and microscopic examination, which takes 2 to 5 days. New-generation intelligent biopsy needles are embedded with diverse micro-sensors at the tip to capture real-time tissue properties during puncture.

Electrochemical impedance spectroscopy is the most mature integrated technology. Distinct tissues (normal, hyperplastic, atypical, and malignant) present characteristic impedance-frequency curves. Micro-electrodes at the needle tip scan within 0.1–10 MHz and differentiate benign and malignant lesions within 0.5 seconds, achieving 92% sensitivity and 87% specificity for breast lesions. Miniaturized optical coherence tomography (OCT) probes feature higher integration: optical fibers are embedded in side windows of the needle tip to acquire microstructural tissue images via rotational scanning with a resolution of 10 μm. It can distinguish ductal carcinoma in situ (with characteristic rosette structures) from invasive carcinoma in real time. In peripheral pulmonary nodule biopsy, OCT-equipped needles verify tumor tissue rather than inflammatory pseudotumor prior to sampling, eliminating unnecessary biopsies with a negative predictive value of 94%.

Microenvironment analysis reveals tumor heterogeneity. The pH value, partial oxygen pressure and metabolite concentration of the tumor microenvironment (TME) directly affect therapeutic response. Multifunctional analytical needles integrate three sensors on 22G tips: pH electrodes, oxygen sensors, and enzyme electrodes for glucose and lactate detection, recording a set of data every 0.5 seconds during puncture.

Clinical studies indicate that lactate concentration in triple-negative breast cancer is 2.3 times higher than that in hormone receptor-positive breast cancer, partially explaining the higher chemotherapy sensitivity of the former. More advanced microdialysis biopsy needles adopt hollow fiber dialysis membranes wrapping the tip. Perfusion fluid circulates at a rate of 0.5 μL/min, and the recovered fluid contains small-molecule metabolites, cytokines and cell-free DNA. In brain tumor biopsy, tissue specimens and microdialysate are collected simultaneously; the former serves for histological diagnosis while the latter for metabolomic analysis, realizing synchronous interpretation of tissue morphology and biological function.

Instant molecular diagnosis reshapes the timeline of therapeutic decision-making. Conventionally, EGFR genetic testing after lung cancer biopsy takes an average of 7 to 10 days, during which tumors may progress. On-needle PCR systems achieve intra-procedural diagnosis. Microfluidic chips are integrated into the biopsy needle handle. After sampling, tissue fluid automatically flows into the chip, completing DNA extraction, PCR amplification and mutation detection within 45 minutes. Currently, 8 lung cancer driver genes including EGFR, ALK and ROS1 can be detected, with 98.7% consistency with central laboratory test results.

Digital pathology needles go even further: miniature cameras at the needle tip capture cellular images, and embedded AI algorithms conduct intraoperative real-time analysis, reaching 97% diagnostic accuracy for papillary thyroid carcinoma and avoiding secondary surgeries.

Integration of biopsy and local therapy accomplishes all-in-one diagnosis and treatment. Radiofrequency biopsy needles represent such integration: they harvest tissue samples first, then deliver radiofrequency energy (460 kHz) at the tip to ablate tissues within a 5 mm radius surrounding the biopsy tract, achieving both diagnosis and treatment of small lesions. For renal tumors smaller than 1.5 cm, diagnosis and radical treatment are completed in one procedure, with a 3-year recurrence-free survival rate of 96%.

Drug-eluting biopsy needles are coated with sustained-release paclitaxel films on the shaft. Microtrauma generated by biopsy enhances drug penetration, resulting in local drug concentration 1,000 times higher than intravenous administration with minimal systemic toxicity. In neoadjuvant therapy for breast cancer, the pathological complete response (pCR) rate within a 2 cm range around the biopsy tract reaches 85%, demonstrating its potential as localized intensive treatment.

Robot assistance and AI decision-making elevate operational precision. The hit rate of manual biopsy for lesions smaller than 1 cm is merely 80%–85%, susceptible to respiratory movement, organ displacement and operator experience. Robotic biopsy systems mount biopsy needles on mechanical arms, achieving 0.8 mm positioning precision via electromagnetic navigation or CT guidance. The detection rate for tiny pulmonary nodules (5–8 mm) is improved from 68% to 95%.

AI preoperative planning systems analyze CT angiography to automatically generate optimal puncture paths avoiding blood vessels. Intraoperative respiratory tracking modules forecast respiratory motion and trigger puncture at the end of exhalation. Post-procedurally, AI instantly evaluates specimen sufficiency and recommends supplementary puncture if sampling is inadequate.